NEW YORK (GenomeWeb News) – Epigenomics announced today that Swiss Life will provide insurance coverage for the firm's Epi proColon 2.0 colorectal cancer test as part of a preventive health program in France.

Swiss Life, France's third-largest private health insurer, is the first French insurer to cover the test, which uses Epigenomics' colorectal cancer biomarker Septin9 in blood plasma, and will reimburse for the test at up to 50 percent of the cost. French Social Security does not cover Epi proColon 2.0, Berlin-based Epigenomics noted.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.

Oct
23
Sponsored by
PerkinElmer

This webinar will address a range of methods for optimizing small RNA library preparation.

Nov
05
Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Nov
29
Sponsored by
Schott

This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.